Perampanel and pregnancy
暂无分享,去创建一个
T. Tomson | T. O'Brien | B. Vazquez | E. Schuck | C. Dobrinsky | T. O’Brien
[1] T. Tomson,et al. Declining malformation rates with changed antiepileptic drug prescribing , 2019, Neurology.
[2] M. Milad,et al. Evaluation of Maternal Drug Exposure Following the Administration of Antenatal Corticosteroids During Late Pregnancy Using Physiologically‐Based Pharmacokinetic Modeling , 2019, Clinical pharmacology and therapeutics.
[3] Minglu Wang,et al. Emerging trends and knowledge structure of epilepsy during pregnancy research for 2000–2018: a bibliometric analysis , 2019, PeerJ.
[4] T. Tomson,et al. Pharmacokinetic variability of valproate during pregnancy – Implications for the use of therapeutic drug monitoring , 2018, Epilepsy Research.
[5] J. Ferry,et al. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters , 2017, Epilepsy Research.
[6] A. Tricco,et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes , 2017, BMC Medicine.
[7] D B Turner,et al. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon , 2017, Biopharmaceutics & drug disposition.
[8] H. Kayserili,et al. Teratogenicity of Antiepileptic Drugs , 2017, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.
[9] G. Koren,et al. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review , 2016, PLoS medicine.
[10] T. Gomes,et al. Antiepileptic use for epilepsy and nonepilepsy disorders , 2016, Neurology.
[11] S. Hernández-Díaz,et al. Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. , 2015, JAMA neurology.
[12] A. Marson,et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential , 2015, Epilepsia.
[13] A. Reimers,et al. New antiepileptic drugs and women , 2014, Seizure.
[14] P. Pennell,et al. Carbamazepine clearance and seizure stability during pregnancy , 2014, Epilepsy & Behavior.
[15] T. Tomson,et al. Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications , 2013, Epilepsia.
[16] M. Bialer. Why are antiepileptic drugs used for nonepileptic conditions? , 2012, Epilepsia.
[17] Lu Gaohua,et al. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. , 2012, British journal of clinical pharmacology.
[18] R. Davis,et al. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. , 2012, Paediatric and perinatal epidemiology.
[19] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[20] B. Kirby,et al. Effects of Pregnancy on CYP3A and P‐glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study , 2008, Clinical pharmacology and therapeutics.
[21] M. Eadie,et al. Seizure control in antiepileptic drug‐treated pregnancy , 2008, Epilepsia.
[22] Robert L Davis,et al. Prescription drug use in pregnancy. , 2004, American journal of obstetrics and gynecology.
[23] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[24] T. Tomson,et al. Epilepsy and Pregnancy: A Prospective Study of Seizure Control in Relation to Free and Total Plasma Concentrations of Carbamazepine and Phenytoin , 1994, Epilepsia.
[25] Wellbutrin,et al. Prescribing Information , 2015, European journal of haematology.